Niemann Pick Disease Type C (Npc) is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Niemann-Pick disease type C (NPC) is a rare autosomal recessive lysosomal storage disorder characterized by intracellular cholesterol trafficking defects leading to neurodegeneration. Unlike Niemann-Pick disease types A and B (which involve acid sphingomyelinase deficiency), NPC results from impaired cholesterol egress from late endosomes and lysosomes[1].
The disease presents with a heterogeneous spectrum of neurological manifestations including cerebellar ataxia, vertical supranuclear gaze palsy (VSGP), dystonia, and progressive cognitive decline. NPC is often referred to as a "childhood Alzheimer's" due to similar neuropathological features including neuronal loss, gliosis, and accumulation of amyloid-beta and tau proteins[2].
NPC is caused by mutations in one of two genes:
| Gene | Protein | Chromosome | Inheritance |
|---|---|---|---|
| NPC1 | NPC1 protein | 11p15.4 | Autosomal recessive |
| NPC2 | NPC2 protein | 14q24.3 | Autosomal recessive |
NPC1 accounts for approximately 95% of all NPC cases, while NPC2 accounts for about 5%[3]. Over 500 disease-causing mutations have been identified in the NPC1 gene, with varying severity correlating with residual protein function.
NPC follows autosomal recessive inheritance. Both copies of the gene must be mutated for disease manifestation. Heterozygous carriers are typically asymptomatic but may have subtle lipid abnormalities.
The NPC proteins play critical roles in intracellular cholesterol trafficking:
Cholesterol Export: NPC1 and NPC2 cooperate to export cholesterol from late endosomes/lysosomes to the plasma membrane and endoplasmic reticulum[4].
Lipid Accumulation: Defective cholesterol egress leads to accumulation of unesterified cholesterol, glycolipids, and phospholipids in lysosomal compartments.
Cellular Dysfunction: Lipid accumulation disrupts multiple cellular processes including:
NPC brain pathology demonstrates:
NPC exhibits variable age of onset:
| Symptom | Frequency | Description |
|---|---|---|
| Cerebellar ataxia | >90% | Gait instability, dysmetria, dysarthria |
| Vertical supranuclear gaze palsy | >80% | Difficulty with vertical eye movements |
| Dystonia | 50-70% | Involuntary muscle contractions |
| Cognitive decline | 60-80% | Progressive dementia |
| Seizures | 30-50% | Various seizure types |
| Dysphagia | 40-60% | Difficulty swallowing |
| Cataplexy | 20-30% | Sudden loss of muscle tone |
Biochemical Testing: Elevated plasma cholestane-3β,5α,6β-triol and lyso-sphingomyosin-509 (lyso-SM-509) are highly sensitive biomarkers[5].
Genetic Testing: Sequencing of NPC1 and NPC2 genes confirms diagnosis.
Filipin Staining: Classic diagnostic test showing unesterified cholesterol accumulation in cultured fibroblasts.
Imaging: MRI reveals cerebellar atrophy, white matter lesions, and cortical thinning.
NPC must be distinguished from:
Miglustat (Zavesca):
Cyclodextrin:
NPC is universally fatal. Life expectancy varies:
Early diagnosis and treatment with miglustat can significantly slow disease progression and extend survival.
Multiple ongoing trials investigate:
The study of Niemann Pick Disease Type C (Npc) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Patterson MC, et al. Niemann-Pick disease type C: A lipid trafficking disorder. Cold Spring Harbor Perspectives in Medicine. 2013;3(6):a007804. DOI:10.1101/cshperspect.a007804 ↩︎
Vanier MT. Niemann-Pick disease type C. Orphanet Journal of Rare Diseases. 2010;5:16. DOI:10.1186/1750-1172-5-16 ↩︎
Wraith JE, et al. Miglustat in patients with Niemann-Pick disease type C (NPC): A randomized, double-blind, placebo-controlled trial. Molecular Genetics and Metabolism. 2009;98(1-2):152-165. ↩︎
loyd-Evans E, Platt FM. Lipid trafficking defects in Niemann-Pick disease type C. Cell Calcium. 2011;49(5):337-342. ↩︎
Jiang X, et al. Lysosomal bile acid transport in health and disease: When NTTs meet NPC1. Journal of Hepatology. 2021;74(5):1234-1246. ↩︎
Ginocchio R, et al. Long-term safety and efficacy of miglustat in pediatric patients with Niemann-Pick disease type C: Results from an open-label extension study. Orphanet Journal of Rare Diseases. 2018;13(1):38. ↩︎
Davidson CD, et al. 2-Hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick disease type C1: A review. Molecular Genetics and Metabolism. 2019;128(4):346-353. ↩︎